Cardiac Imaging Recommendation for HCM Screening
You need a comprehensive cardiac MRI (CMR) with late gadolinium enhancement (LGE) as your primary imaging modality, supplemented by stress echocardiography to assess for exercise-induced left ventricular outflow tract obstruction (LVOTO), given your endurance cycling activity and negative preliminary genetic testing 1, 2.
Why Cardiac MRI is Essential
Your negative genetic test does not rule out HCM. The 2024 AHA/ACC guidelines emphasize that genetic testing in HCM probands should focus on strong evidence genes (MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1), but approximately 30-40% of HCM patients have no identifiable pathogenic variant even with comprehensive testing 1. The extent of your genetic testing is unknown, which is a critical gap.
Cardiac MRI is superior to echocardiography alone because it:
- Detects segmental hypertrophy in areas poorly visualized by echo (anterolateral free wall, apex) 3
- Identifies myocardial fibrosis through LGE, which has prognostic significance 2, 4
- Provides precise measurement of wall thickness and cardiac mass 5
- Can detect subtle phenotypic features in the "gray zone" between athlete's heart and early HCM 2
Additional Testing Algorithm
1. Stress Echocardiography with CPET (Cardiopulmonary Exercise Testing)
- Critical for endurance athletes because LVOTO may only manifest during exercise 6, 7
- Measures peak VO2, which predicts clinical outcomes and heart failure progression 7
- Assesses exercise-induced diastolic dysfunction and pulmonary pressures 7
- Your case report parallel showed an athlete with normal resting imaging but severe LVOTO (150 mmHg gradient) only on stress testing 6
2. Extended Holter Monitoring (48-72 hours)
- Screen for ventricular arrhythmias during training
- Assess for chronotropic incompetence, which associates with adverse outcomes 7
3. Repeat/Expanded Genetic Testing
- If your initial test was a limited panel, pursue comprehensive sarcomere gene sequencing 1
- Consider testing for HCM phenocopies (storage diseases, mitochondrial disorders) given your prolonged testosterone use, which can cause cardiac hypertrophy 1
Critical Testosterone Consideration
Your 15+ years of testosterone replacement therapy complicates the picture. While the FDA label 8 doesn't specifically list cardiac hypertrophy as a primary concern, exogenous androgens can cause left ventricular hypertrophy independent of HCM. This makes distinguishing pathological from physiological (athlete's heart + testosterone effect) hypertrophy even more challenging. CMR with tissue characterization (native T1 mapping, T2 values) can help differentiate these entities 2.
Common Pitfalls to Avoid
- Don't rely solely on echocardiography - it misses 15-20% of HCM cases, particularly apical variants 3, 9
- Don't assume negative genetics = no HCM - the guidelines explicitly state that cascade genetic testing is not useful when no pathogenic variant is found, but this doesn't exclude the diagnosis in you as the potential proband 1
- Don't skip stress testing - resting studies miss exercise-induced obstruction in symptomatic athletes 6
- Don't ignore the testosterone variable - discuss with your cardiologist whether temporary cessation might clarify the diagnosis
Ongoing Surveillance
If initial comprehensive workup is negative, the 2015 Bethesda guidelines suggest that genotype-positive/phenotype-negative individuals can participate in competitive athletics 3. However, you need serial imaging every 12-24 months through age 20-25 (if younger) or every 3-5 years if older, as phenotypic conversion can occur at any age 3, 10.
The combination of CMR with LGE, stress echo with CPET, and comprehensive genetic retesting provides the most robust assessment for ruling out HCM in your high-risk scenario as an endurance athlete on long-term testosterone therapy.